Smart Mind Maps in Promoting Safe Administration of High-Alert Medications (HAMs- PICU)

January 3, 2026 updated by: Mansoura University

The Effectiveness of Smart Mind Maps in Promoting Safe Administration of High-Alert Medications Among Nurses in the Pediatric Intensive Care Unit

In PICU setting, drug administration, monitoring, and prescribing errors made up most cases (54%) of MEs . Emphasizes these issues requires a multifaceted approach, including staff training, creation of innovative cognitive frameworks, use of electronic prescribing systems, and the promotion of a safety-awareness within healthcare settings. Recently, mind mapping has been applied in the field of nursing education as an advanced conceptual tool. It uses a technique of combining drawings with words to build memory associations between a topic keyword and image, color, or other link allowing learners to effectively store and extract information

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study aims to evaluate the effectiveness of smart mind maps in promoting safe administration of high-alert medications among nurses in the pediatric intensive care unit. Designing a mind map using AI holds significant value for nurses working in the PICU. AI-powered mind maps can help nurses organize complex patient information more efficiently, enabling quicker decision-making and improved care planning. By integrating AI, the mind map can automatically update with real-time data, alert nurses to critical changes, and even suggest evidence-based interventions. This not only enhances patient safety and care quality but also reduces cognitive load and streamlines communication among the healthcare team .

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: doaa osman ibrahim doaa ibrahim- assistant lecturer, assistant lecturer
  • Phone Number: 020-01069637084
  • Email: doaaibrahim93@mans.edu.eg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion criteria:

  • Nurses on duty in the PICU (who directly handled HAM) irrespectively to their age, sex, educational level.

Exclusion Criteria:

  • Nurses who do not handle with HAM

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: one group pretest/post test
PICU nurses who directly handled HAM
Other: smart mind mapsde
designing a smart mind maps as an advanced conceptual tool to help nurses understand well about HAMs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tool I: A Structured Assessment Questionnaire
Time Frame: 2 weeks

It will be developed by the researcher which will consist of two parts:

Part 1: Socio-demographic Characteristics and Professional Data of Studied Nurses part 2: Knowledge Assessment Tool on AI and Mind Mapping for Nurses (pre/posttest)
2 weeks
Tool II: Nurses' Knowledge Regarding Safe Use of High-Alert Medications (HAMs)
Time Frame: 1 month
It will be developed to collect data necessary for evaluating nurses' knowledge related to safe use of high-alert medications. The assessment will encompass key domains such as the definition and classification of HAMs, safety precautions during drug administration (including delivery routes and dosage accuracy), and drug regulation (including proper storage, documentation, and handling procedures).
1 month
Tool III: Observational Checklist for Safe Handling of High Alert Medications
Time Frame: 2 month
It will be developed by the researcherto objectively assess nurses' practices related to the safe handling of high-alert medications in PICUs according to the international recognized guidelines and evidence-based protocols.
2 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mansoura University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 4, 2026

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

September 8, 2025

First Submitted That Met QC Criteria

January 3, 2026

First Posted (Actual)

January 6, 2026

Study Record Updates

Last Update Posted (Actual)

January 6, 2026

Last Update Submitted That Met QC Criteria

January 3, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Mind Map high alert medication

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No individual participant data (IPD) will be shared because the study involves sensitive clinical data from a small population, and sharing may pose confidentiality risks despite de-identification.

Access Criteria:

Not applicable. IPD will not be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nurses

Clinical Trials on smart mind mapsde

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe